Price-to-Book

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

With French state backing, Eutelsat secures €1bn to build its next-gen OneWeb LEO constellation, intensifying the global satellite internet race.

A new report shows the carbon removal market has the tools to fight climate change, but widespread corporate inaction threatens to strand vital projects.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A spike in layoffs to 14-year highs clashes with extreme investor optimism, raising fears of a major market correction on the horizon for 2026.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Pan-European exchange reports a strong start to 2026, fueled by a historic defense IPO and a dramatic spike in foreign exchange and metals trading.

A new bond issue strengthens Agilyx's finances, funding a dual strategy focused on immediate earnings and long-term tech licensing in plastic recycling.

Industrial conglomerate Schouw & Co. offers a fee for bondholder consent to spin off its aquaculture giant BioMar, a move that could unlock value but alters risk.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

Veteran investor Stephen Riddell partners with Gallatin Point to launch DS2 Capital, a new firm poised to navigate the complex structured credit market.

A new report reveals a grim reality: the typical American worker has under $1,000 for retirement. Is the system, not the saver, fundamentally broken?

A new report reveals a looming crisis: rising healthcare costs will consume more than 100% of Social Security benefits for future generations of retirees.

IUOE Local 150 backs Speaker Welch for State Central Committeeperson, signaling a major power play in Illinois Democratic politics post-Danny Davis.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.